Drug Information
Drug General Information | Top | |||
---|---|---|---|---|
Drug ID |
D0W5IN
|
|||
Former ID |
DNC012045
|
|||
Drug Name |
(2-Methyl-indol-1-yl)-propyl-pyridin-4-yl-amine
|
|||
Synonyms |
CHEMBL154945; (2-Methyl-indol-1-yl)-propyl-pyridin-4-yl-amine; SCHEMBL7608050; BDBM50048573
Click to Show/Hide
|
|||
Drug Type |
Small molecular drug
|
|||
Indication | Discovery agent [ICD-11: N.A.] | Investigative | [1] | |
Structure |
Download2D MOL |
|||
Formula |
C17H19N3
|
|||
Canonical SMILES |
CCCN(C1=CC=NC=C1)N2C(=CC3=CC=CC=C32)C
|
|||
InChI |
1S/C17H19N3/c1-3-12-19(16-8-10-18-11-9-16)20-14(2)13-15-6-4-5-7-17(15)20/h4-11,13H,3,12H2,1-2H3
|
|||
InChIKey |
JCEBKNUYKMFQGZ-UHFFFAOYSA-N
|
|||
PubChem Compound ID |
Target and Pathway | Top | |||
---|---|---|---|---|
Target(s) | Adrenergic receptor alpha-2A (ADRA2A) | Target Info | Inhibitor | [1] |
Adrenergic receptor alpha-2B (ADRA2B) | Target Info | Inhibitor | [1] | |
Adrenergic receptor alpha-2C (ADRA2C) | Target Info | Inhibitor | [1] | |
KEGG Pathway | cGMP-PKG signaling pathway | |||
Neuroactive ligand-receptor interaction | ||||
Panther Pathway | Alpha adrenergic receptor signaling pathway | |||
Heterotrimeric G-protein signaling pathway-Gi alpha and Gs alpha mediated pathway | ||||
Reactome | Adrenoceptors | |||
Adrenaline signalling through Alpha-2 adrenergic receptor | ||||
Adrenaline,noradrenaline inhibits insulin secretion | ||||
G alpha (i) signalling events | ||||
G alpha (z) signalling events | ||||
Surfactant metabolism | ||||
WikiPathways | Monoamine GPCRs | |||
GPCRs, Class A Rhodopsin-like | ||||
Platelet Aggregation (Plug Formation) | ||||
Integration of energy metabolism | ||||
GPCR ligand binding | ||||
GPCR downstream signaling |
References | Top | |||
---|---|---|---|---|
REF 1 | Synthesis and structure-activity relationships of N-propyl-N-(4-pyridinyl)-1H-indol-1-amine (besipirdine) and related analogs as potential therapeu... J Med Chem. 1996 Jan 19;39(2):570-81. |
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.